Perspective Therapeutics, Inc.

CATX

Explore Our Financial Data > Companies > Micro Cap > Perspective Therapeutics, Inc.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
CATX
CIK0000728387
SIC3841
SectorManufacturing
Industry CategoryMedical Equipment
Industry GroupSurgical, Medical, And Dental Instruments And Supplies

Contact

Address2401 ELLIOTT AVENUE, SUITE 320, SEATTLE, WA, 98121
Website isoray.com
Phone206-676-0900
CEOLori A. Woods
Employees70

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$1.47 million
Pre-Tax Income$-86.78 million
Net Income$-85.17 million
Net Income to Common$-85.17 million
EPS$-1.18
View All
Balance Sheet
Cash$44.41 million
Assets$329.35 million
Liabilities$44.70 million
Common Equity$284.64 million
Liabilities & Equity$329.35 million
View All
Cash Flow Statement
Net Income$-85.17 million
Cash From Operating Activities$-53.72 million
Cash From Investing Activities$-177.20 million
Cash From Financing Activities$133.03 million
Change in Cash$-97.89 million
View All
Calculations
NOPAT$-69.80 million
EBITDA$-95.63 million
Price to EarningsN/A
Price to Book$0.96
ROE-33.11%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

SEATTLE, July 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2025 taking place October 17 to 21, 2025 in Berlin, Germany. ESMO plans to release fur

Article Link

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that it will report its second quarter 2025 financial results and provide a business update on Wednesday, August 13, 2025 before the market opens. The press release will be available on the newsroom section of the Company’s website at https://perspectivetherap

Article Link

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced two presentations on its assets being delivered at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting taking place June 21-24, 2025 in New Orleans, Louisiana. Lead authorAbstract TitlePresentation DetailsStephen Graves[212Pb]Pb-VMT-α-N

Article Link

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical dataOn track to submit further clinical updates to scientific congresses in 2H 2025, including longer safety follow-u

Article Link

3 Promising Penny Stocks With Market Caps Over $90M

The market has been flat over the last week, but it has shown a 13% rise over the past year, with earnings projected to grow by 14% annually in the coming years. In this context, identifying promising stocks involves looking for those that combine affordability with solid financials. While penny stocks might seem like an outdated term, they remain relevant as they often represent smaller or newer companies offering potential growth opportunities.

Article Link